Quest Diagnostics IncDGX

Quest Diagnostics Incorporated reported revenue of $3.04bn for the quarter ended 30 June 2026, alongside net income of $320m and diluted earnings per share of $2.84, according to the company’s latest 10-Q lodged with the SEC on 23 July 2026. Operating income clocked in at $459m, while operating cash flow jumped to $875m, more than covering the $252m spent on property, plant and equipment. The balance sheet shows $16.94bn in assets and $7.52bn in shareholders’ equity, with $626m of cash and equivalents on hand.

Quest is the brand behind a sprawling network of clinical laboratories that process routine and specialty tests for employers, health plans, hospitals and life-sciences sponsors. The employer solutions page promises configurable programmes to “engage and retain employees,” while the health-plan rail pitches HIPAA-covered lab services, and the pharma arm markets “all phases of clinical trial testing.” The company’s operating model is simple: run tests, bill payers, collect cash. The filings, however, reveal a more textured reality-one where the cash-generative engine is humming, yet capex and inventory are rising in tandem. The revenue figure is big enough to impress, but the $233m inventory line suggests Quest is stocking up on supplies like a pharmacy preparing for flu season.

The 10-Q shows diluted weighted average shares outstanding at 112m, a figure that anchors the $2.84 EPS despite the company’s cash machine. The 11-K pension filing quietly records $29,226 of Quest stock sold by the plan in 2025, a rounding error next to the $3bn revenue headline but a reminder that optics and arithmetic don’t always align. The board’s matching-gift policy looks generous on paper-100% cash match after 12 months-but the cash outlay sits with the operating company, not the balance sheet’s war chest. Meanwhile, the joint venture with Corewell Health in Michigan, announced with corporate bonhomie, arrives without a single SEC filing or cash figure, leaving investors to guess whether it’s a growth lever or a PR placebo.

The company’s core operating metrics are strong, but the filings also expose cracks in the polished narrative. Cash from operations at $875m is healthy, yet capex at $252m is eating into free cash flow. Inventory at $233m is rising while revenue grows, a dynamic worth watching if supply chains or demand shift. The lack of disclosure around the Corewell joint venture’s economics is notable, as is the minuscule scale of the company’s own pension-plan stock sales relative to the business’s size. The filings don’t lie, but they also don’t always explain.

For readers who like their market stories served with receipts, the SEC EDGAR index for Quest Diagnostics is the single source of truth, linking every filing, 8-K and 4 from the past year. The companyfacts JSON and submissions JSON round out the picture, offering machine-readable confirmation of the numbers and events already cited. Want to dig deeper? Start there. The product rails-employer services, health-plan services and health-system services-round out the operating picture, but they don’t change the filings. If you’re hunting for colour beyond the numbers, the joint-venture press release is the most visible public development, yet it lacks the hard data investors typically crave.

The tension in this file sits between the company’s cash-generative engine and the opacity around certain partnerships. The filings show a business printing cash, but the lack of granularity around the Corewell joint venture and the modest scale of the pension-plan stock sales leave questions unanswered. Until Quest releases more detail on the venture’s economics or pares back the inventory build, the polished platform story will keep running ahead of the prosaic balance sheet.